The trial also reported a positive trend in OS, favoring the durvalumab + olaparib arm.
← all excerpts
Clinical practice guidelines for uterine corpus cancer: an update to the Korean Society of Gynecologic Oncology guidelines.
1
—
—
The trial also reported a positive trend in OS, favoring the durvalumab + olaparib arm.